Displaying drugs 11301 - 11325 of 12185 in total
IDM-2
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
Filaminast
Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Experimental
Matched Description: … Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). …
Porfiromycin
Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.
Investigational
Matched Description: … Porfiromycin is a substance that is being studied in the treatment of cancer. …
Diridavumab
Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Investigational
Matched Description: … Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics …
Swertia japonica whole flowering
Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products …
Bixalomer
Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).
Investigational
Matched Description: … Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 …
Orilanolimab
Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Investigational
Matched Description: … Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects …
Ro 24-7429
Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).
Investigational
Matched Description: … Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With …
HIV Integrase Inhibitor
HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects).
Investigational
Matched Description: … HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose …
Imsidolimab
Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).
Investigational
Matched Description: … Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and …
NY-ESO-1 peptide vaccine
NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).
Investigational
Matched Description: … It contains a peptide derived from the cancer-testis antigen (NY-ESO-1). …
FLT201
FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta (β)-glucocerebrosidase variant 85 (GCasevar85)
Investigational
Matched Description: … FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression …
Tanfanercept
Tanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease).
Investigational
Matched Description: … Tanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and …
Tecadenoson
Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Investigational
Matched Description: … Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for …
PSN9301
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
Matched Description: … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical …
Dimenoxadol
Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.
Experimental
Illicit
Matched Description: … In the United States it is classified as a Schedule I controlled drug. ... It is structurally similar to methadone and is a benzilic acid derivative. …
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine
4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. This compound belongs to the fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.
Experimental
Matched Description: … 4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine is a solid. ... These are compounds containing one or more fluorine atoms attached to a benzene ring. …
Trefentanil
Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. It is more potent and shorter acting than alfentanil. Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.
Experimental
Matched Description: … Trefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. …
Bempegaldesleukin
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
Investigational
Matched Description: … Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination ... With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy …
LX6171
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
Investigational
Volixibat
Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH.
Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational
Matched Description: … Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane ... Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for ... granted fast track status by the Food and Drug Administration due to promising initial results and a …
Tasosartan
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
DP-b99
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Matched Description: … DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N ... ,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment …
Methylthioinosine
An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
Experimental
Matched Description: … An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position. …
IPH 2101
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Matched Description: … IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia …
Displaying drugs 11301 - 11325 of 12185 in total